Findings

What do systematic reviews say?

5 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Infliximab 5 mg/kg vs purine analogues

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.7 [0.46, 1.06]
2 studies · 355 participants
Low

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.03 [0.07, 15.79]
1 study · 63 participants
Very low

Infliximab 5 mg/kg vs infliximab 20 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.26 [0.7, 2.25]
1 study · 220 participants
Low

Infliximab 5 mg/kg and purine analogues vs purine analogues

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.87 [0.63, 1.21]
4 studies · 603 participants
Low